scorecardresearch

Saturday, November 21, 2026

Support our Journalism

Depth, context and analysis

Subscribe
HomeFeaturesHeadset to slow Alzheimer’s fails in major trial. Shows promise in milder...

Headset to slow Alzheimer’s fails in major trial. Shows promise in milder cases

The findings were presented by US-based Cognito Therapeutics at the Clinical Trials on Alzheimer’s Disease conference in Boston.

Stay updated with ThePrint:

New Delhi: An experimental headset that used light and sound therapy to stimulate brain activity failed to significantly slow cognitive decline in people with Alzheimer’s disease, the results of a landmark clinical trial involving 673 patients confirmed.

The findings were presented by US-based Cognito Therapeutics at the Clinical Trials on Alzheimer’s Disease conference in Boston on 16 November. They definitively showed that patients who used the company’s Spectris AD device did not perform any better than those who received a sham treatment after a year.

“The trial was negative,” Eric McDade, a neurologist at Washington University School of Medicine who was not involved in the research, told Nature. The company did, however, report that results among patients with mild or early-onset Alzheimer’s were more encouraging.

How the treatment works

The Spectris AD headset is a combination of light-emitting goggles and rhythmic headphones that expose the wearer to synchronised flashes of light and sound 40 times a second, or a frequency of 40 hertz.

The purpose of these flashes is to stimulate the brain by strengthening gamma brain waves, which are associated with attention, memory, and other higher brain functions. Previous experiments on mice suggested that stimulating these waves reduced the accumulation of amyloid-beta, the protein behind the plaque that causes Alzheimer’s disease.

In the latest Phase 3 HOPE trial on humans, patients with mild to moderate Alzheimer’s were assigned to either use the Spectris AD headset or a sham device for an hour every day for over 12 months. During this period, researchers assessed differences in the patients’ cognition and ability to perform everyday tasks with the use of a combined 156-point scale.

At the end of the trial, the patients who used the sham device had 8.97 points worth of cognitive decline, while the Spectris headset users suffered 8.82 points worth of cognitive decline. The difference of 0.15 points was considered statistically insignificant. 

Encouraging findings in milder cases

In a prespecified subgroup of 395 patients with mild Alzheimer’s, the company reported slowdowns of up to 60 per cent on separate benchmarks such as the What Matters Most framework, which had been developed through research with people living with Alzheimer’s disease and their care partners. Despite that, the evidence was not strong enough on two of the five measures to rule out that the improvements were not by chance.

Cognito chief executive Christian Howell acknowledged the overall failure, saying in a company statement that the researchers had hoped to see an effect across the broader population, “and we did not”.

On a more positive note, Cognito reported that the latest device was generally well-tolerated by patients, although they did report more headaches and instances of tinnitus.


Also read: Alcohol alters immune cells that fight cancer. Here’s how


Researchers urge caution

The results of the Phase 3 HOPE trial serve only to reinforce the findings of a smaller trial with 76 patients that found negligible benefits from the treatments, which was published in Frontiers in Neurology in 2024.

Rob Howard, a psychiatrist at University College London, told Nature that the trial had failed its primary objective.

“If this was a drug, such a clear failure would mean that a company would not proceed to seek regulatory approval,” he said.

In spite of this, Cognito plans to seek US Food and Drug Administration authorisation for treating mild Alzheimer’s, while continuing to investigate the therapy’s long-term effects, where more controlled trials will be required to see if the benefits seen can be reproduced reliably.

(Edited by Prasanna Bachchhav)

Subscribe to our channels on YouTube, Telegram & WhatsApp

For readers who want the full picture.

You read our articles closely. Subscribe to go further, with exclusive newsletters in your inbox, flagship events hosted by Shekhar Gupta, AMAs with our senior editors, the chance to write under your own byline, and more.

Subscribe to ThePrint →

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular